Role of the TSG101 gene in Epstein-Barr virus late gene transcription

Journal of Virology

Volumn 81, Issue 5, 2007, Pages 2459-2471

  Chua, Huey Huey ^a   Lee, Heng Huan ^a   Chang, Shih Shin ^a   Lu, Chih Chung ^a   Yeh, Te Huei ^b   Hsu, Tsuey Ying ^a   Cheng, Tzu Hao ^c   Cheng, Jiin Tsuey ^d   Chen, Mei Ru ^a   Tsai, Ching Hwa ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; COMPLEMENTARY DNA; IMMEDIATE EARLY PROTEIN; PROTEIN KINASE B; PROTEIN RTA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ARTICLE; BCLF1 GENE; BDLF3 GENE; BILF2 GENE; BLLF1 GENE; BLRF2 GENE; CELL MEMBRANE; CONTROLLED STUDY; DNA MICROARRAY; DNA VIRUS; ENDOSOME; EPSTEIN BARR VIRUS; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; RNA VIRUS; TRANSACTIVATION; TSG101 GENE; VIRUS GENE; VIRUS PARTICLE; VIRUS REACTIVATION; VIRUS REPLICATION;

BASE SEQUENCE; CELL LINE, TUMOR; DNA, VIRAL; DNA-BINDING PROTEINS; EPSTEIN-BARR VIRUS INFECTIONS; GENES, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; IMMEDIATE-EARLY PROTEINS; PROMOTER REGIONS (GENETICS); RNA, SMALL INTERFERING; TRANS-ACTIVATION (GENETICS); TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; UBIQUITIN-CONJUGATING ENZYMES; VIRAL PROTEINS; VIRUS REPLICATION;

DNA VIRUSES; HUMAN HERPESVIRUS 4; RNA VIRUSES;

EID: 33847243278     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02289-06     Document Type: Article

References (75)

1. Adamson, A. L., D. Darr, E. Holley-Guthrie, R. A. Johnson, A. Mauser, J. Swenson, and S. Kenney. 2000. Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. J. Virol. 74:1224-1233.
2. Bishop, N., and P. Woodman. 2001. TSG101/mammalian VPS23 and mammalian VPS28 interact directly and are recruited to VPS4-induced endosomes. J. Biol. Chem. 276:11735-11742.
3. Bouamr, F., J. A. Melillo, M. Q. Wang, K. Nagashima, M. de Los Santos, A. Rein, and S. P. Goff. 2003. PPPYVEPTAP motif is the late domain of human T-cell leukemia virus type 1 Gag and mediates its functional interaction with cellular proteins Nedd4 and Tsg101. J. Virol. 77:11882-11895.
4. Burgdorf, S., P. Leister, and K. H. Scheidtmann. 2004. TSG101 interacts with apoptosis-antagonizing transcription factor and enhances androgen receptor-mediated transcription by promoting its monoubiquitination. J. Biol. Chem. 279:17524-17534.
5. Chang, L. K., J. Y. Chung, Y. R. Hong, T. Ichimura, M. Nakao, and S. T. Liu. 2005. Activation of Sp1-mediated transcription by Rta of Epstein-Barr virus via an interaction with MCAF1. Nucleic Acids Res. 33:6528-6539.
6. Chang, Y., S. S. Chang, H. H. Lee, S. L. Doong, K. Takada, and C. H. Tsai. 2004. Inhibition of the Epstein-Barr virus lytic cycle by Zta-targeted RNA interference. J. Gen. Virol. 85:1371-1379.
7. Chang, Y., S. D. Cheng, and C. H. Tsai. 2002. Chromosomal integration of Epstein-Barr virus genomes in nasopharyngeal carcinoma cells. Head Neck 24:143-150.
8. Chang, Y., H. H. Lee, Y. T. Chen, J. Lu, S. Y. Wu, C. W. Chen, K. Takada, and C. H. Tsai. 2006. Induction of the early growth response 1 gene by Epstein-Barr virus lytic transactivator Zta. J. Virol. 80:7748-7755.
9. Chang, Y., T. C. Lee, J. C. Li, T. L. Lai, H. H. Chua, C. L. Chen, S. L. Doong, C. K. Chou, T. S. Sheen, and C. H. Tsai. 2005. Differential expression of osteoblast-specific factor 2 and polymeric immunoglobulin receptor genes in nasopharyngeal carcinoma. Head Neck 27:873-882.
10. Chang, Y., C. H. Tung, Y. T. Huang, J. Lu, J. Y. Chen, and C. H. Tsai. 1999. Requirement for cell-to-cell contact in Epstein-Barr virus infection of nasopharyngeal carcinoma cells and keratinocytes. J. Virol. 73:8857-8866.
11. Chasserot-Golaz, S., C. Schuster, J. B. Dietrich, G. Beck, and D. A. Lawrence. 1988. Antagonistic action of RU38486 on the activity of transforming growth factor-beta in fibroblasts and lymphoma cells. J. Steroid Biochem. 30:381-385.
12. Chen, L. W., P. J. Chang, H. J. Delecluse, and G. Miller. 2005. Marked variation in response of consensus binding elements for the Rta protein of Epstein-Barr virus. J. Virol. 79:9635-9650.
13. Countryman, J., and G. Miller. 1985. Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc. Natl. Acad. Sci. USA 82:4085-4089.
14. Darr, C. D., A. Mauser, and S. Kenney. 2001. Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation. J. Virol. 75:6135-6142.
15. El-Guindy, A. S., and G. Miller. 2004. Phosphorylation of Epstein-Barr virus ZEBRA protein at its casein kinase 2 sites mediates its ability to repress activation of a viral lytic cycle late gene by Rta. J. Virol. 78:7634-7644.
16. Faggioni, A., C. Zompetta, S. Grimaldi, G. Barile, L. Frati, and J. Lazdins. 1986. Calcium modulation activates Epstein-Barr virus genome in latently infected cells. Science 232:1554-1556.
17. Farina, A., R. Feederle, S. Raffa, R. Gonnella, R. Santarelli, L. Frati, A. Angeloni, M. R. Torrisi, A. Faggioni, and H. J. Delecluse. 2005. BFRF1 of Epstein-Barr virus is essential for efficient primary viral envelopment and egress. J. Virol. 79:3703-3712.
18. Feederle, R., M. Kost, M. Baumann, A. Janz, E. Drouet, W. Hammerschmidt, and H. J. Delecluse. 2000. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J. 19:3080-3089.
19. Garrus, J. E., U. K. von Schwedler, O. W. Pornillos, S. G. Morham, K. H. Zavitz, H. E. Wang, D. A. Wettstein, K. M. Stray, M. Cote, R. L. Rich, D. G. Myszka, and W. I. Sundquist. 2001. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 107:55-65.
20. Gong, M., and E. Kieff. 1990. Intracellular trafficking of two major Epstein-Barr virus glycoproteins, gp350/220 and gp110. J. Virol. 64:1507-1516.
21. Granato, M., A. Farina, R. Gonnella, R. Santarelli, L. Frati, A. Faggioni, and A. Angeloni. 2006. Regulation of the expression of the Epstein-Barr virus early gene BFRF1. Virology 347:109-116.
22. Gruffat, H., E. Manet, A. Rigolet, and A. Sergeant. 1990. The enhancer factor R of Epstein-Barr virus (EBV) is a sequence-specific DNA binding protein. Nucleic Acids Res. 18:6835-6843.
23. Hall, A. H., and K. A. Alexander. 2003. RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells. J. Virol. 77:6066-6069.
24. Hardwick, J. M., P. M. Lieberman, and S. D. Hayward. 1988. A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J. Virol. 62:2274-2284.
25. Hewitt, E. W., L. Duncan, D. Mufti, J. Baker, P. G. Stevenson, and P. J. Lehner. 2002. Ubiquitylation of MHC class I by the K3 viral protein signals internalization and TSG101-dependent degradation. EMBO J. 21:2418-2429.
26. Holley-Guthrie, E. A., E. B. Quinlivan, E. C. Mar, and S. Kenney. 1990. The Epstein-Barr virus (EBV) BMRF1 promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner. J. Virol. 64:3753-3759.
27. Hsu, T. Y., Y. Chang, P. W. Wang, M. Y. Liu, M. R. Chen, J. Y. Chen, and C. H. Tsai. 2005. Reactivation of Epstein-Barr virus can be triggered by an Rta protein mutated at the nuclear localization signal. J. Gen. Virol. 86:317-322.
28. Huang, J., G. Liao, H. Chen, F. Y. Wu, L. Hutt-Fletcher, G. S. Hayward, and S. D. Hayward. 2006. Contribution of C/EBP proteins to Epstein-Barr virus lytic gene expression and replication in epithelial cells. J. Virol. 80:1098-1109.
29. Johannsen, E., M. Luftig, M. R. Chase, S. Weicksel, E. Cahir-McFarland, D. Illanes, D. Sarracino, and E. Kieff. 2004. Proteins of purified Epstein-Barr virus. Proc. Natl. Acad. Sci. USA 101:16286-16291.
30. Kenney, S., E. Holley-Guthrie, E. C. Mar, and M. Smith. 1989. The Epstein-Barr virus BMLF1 promoter contains an enhancer element that is responsive to the BZLF1 and BRLF1 transactivators. J. Virol. 63:3878-3883.
31. Kieff, E., and A. B. Rickinson. 2001. Epstein-Barr virus and its replication, p. 2541-2548. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 4th ed., vol. 2. Lippincott, Williams and Wilkins, Philadelphia, PA.
32. Kurilla, M. G., T. Heineman, L. C. Davenport, E. Kieff, and L. M. Hutt-Fletcher. 1995. A novel Epstein-Barr virus glycoprotein gp150 expressed from the BDLF3 open reading frame. Virology 209:108-121.
33. Lagenaur, L. A., and J. M. Palefsky. 1999. Regulation of Epstein-Barr virus promoters in oral epithelial cells and lymphocytes. J. Virol. 73:6566-6572.
34. Li, J. S., B. S. Zhou, G. E. Dutschman, S. P. Grill, R. S. Tan, and Y. C. Cheng. 1987. Association of Epstein-Barr virus early antigen diffuse component and virus-specified DNA polymerase activity. J. Virol. 61:2947-2949.
35. Li, L., and S. N. Cohen. 1996. Tsg101: a novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell 85:319-329.
36. Li, L., J. Liao, J. Ruland, T. W. Mak, and S. N. Cohen. 2001. A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control. Proc. Natl. Acad. Sci. USA 98:1619-1624.
37. Lin, C. T., W. Y. Chan, W. Chen, H. M. Huang, H. C. Wu, M. M. Hsu, S. M. Chuang, and C. C. Wang. 1993. Characterization of seven newly established nasopharyngeal carcinoma cell lines. Lab. Investig. 68:716-727.
38. Lin, J. C., J. E. Shaw, M. C. Smith, and J. S. Pagano. 1979. Effect of 12-O-tetradecanoyl-phorbol-13-acetate on the replication of Epstein-Barr virus. I. Characterization of viral DNA. Virology 99:183-187.
39. Lin, J. C., N. D. Sista, F. Besencon, J. Kamine, and J. S. Pagano. 1991. Identification and functional characterization of Epstein-Barr virus DNA polymerase by in vitro transcription-translation of a cloned gene. J. Virol. 65:2728-2731.
40. Liu, C., N. D. Sista, and J. S. Pagano. 1996. Activation of the Epstein-Barr virus DNA polymerase promoter by the BRLF1 immediate-early protein is mediated through USF and E2F. J. Virol. 70:2545-2555.
41. Liu, P., and S. H. Speck. 2003. Synergistic autoactivation of the Epstein-Barr virus immediate-early BRLF1 promoter by Rta and Zta. Virology 310:199-206.
42. Liu, R. T., C. C. Huang, H. L. You, F. F. Chou, C. C. Hu, F. P. Chao, C. M. Chen, and J. T. Cheng. 2002. Overexpression of tumor susceptibility gene TSG101 in human papillary thyroid carcinomas. Oncogene 21:4830-4837.
43. Lo, Y. M., L. Y. Chan, K. W. Lo, S. F. Leung, J. Zhang, A. T. Chan, J. C. Lee, N. M. Hjelm, P. J. Johnson, and D. P. Huang. 1999. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 59:1188-1191.
44. Lu, C. C., Y. Y. Jeng, C. H. Tsai, M. Y. Liu, S. W. Yeh, T. Y. Hsu, and M. R. Chen. 2006. Genome-wide transcription program and expression of the Rta responsive gene of Epstein-Barr virus. Virology 345:358-372.
45. Lu, Q., L. W. Hope, M. Brasch, C. Reinhard, and S. N. Cohen. 2003. TSG101 interaction with HRS mediates endosomal trafficking and receptor downregulation. Proc. Natl. Acad. Sci. USA 100:7626-7631.
46. Luka, J., B. Kallin, and G. Klein. 1979. Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology 94:228-231.
47. Mackett, M., M. J. Conway, J. R. Arrand, R. S. Haddad, and L. M. Hutt-Fletcher. 1990. Characterization and expression of a glycoprotein encoded by the Epstein-Barr virus BamHI I fragment. J. Virol. 64:2545-2552.
48. Manet, E., A. Rigolet, H. Gruffat, J. F. Giot, and A. Sergeant. 1991. Domains of the Epstein-Barr virus (EBV) transcription factor R required for dimerization, DNA binding and activation. Nucleic Acids Res. 19:2661-2667.
49. Martin-Serrano, J., T. Zang, and P. D. Bieniasz. 2001. HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat. Med. 7:1313-1319.
50. Mettenleiter, T. C. 2004. Budding events in herpesvirus morphogenesis. Virus Res. 106:167-180.
51. Muromoto, R., K. Sugiyama, T. Yamamoto, K. Oritani, K. Shimoda, and T. Matsuda. 2004. Physical and functional interactions between Daxx and TSG101. Biochem. Biophys. Res. Commun. 316:827-833.
52. Nemerow, G. R., C. Mold, V. K. Schwend, V. Tollefson, and N. R. Cooper. 1987. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. J. Virol. 61:1416-1420.
53. Ponting, C. P., Y. D. Cai, and P. Bork. 1997. The breast cancer gene product TSG101: a regulator of ubiquitination? J. Mol. Med. 75:467-469.
54. Pornillos, O., S. L. Alam, R. L. Rich, D. G. Myszka, D. R. Davis, and W. I. Sundquist. 2002. Structure and functional interactions of the Tsg101 UEV domain. EMBO J. 21:2397-2406.
55. Quinlivan, E. B., E. A. Holley-Guthrie, M. Norris, D. Gutsch, S. L. Bachenheimer, and S. C. Kenney. 1993. Direct BRLF1 binding is required for cooperative BZLF1/BRLF1 activation of the Epstein-Barr virus early promoter, BMRF1. Nucleic Acids Res. 21:1999-2007.
56. Ragoczy, T., L. Heston, and G. Miller. 1998. The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes. J. Virol. 72:7978-7984.
57. Ragoczy, T., and G. Miller. 2001. Autostimulation of the Epstein-Barr virus BRLF1 promoter is mediated through consensus Sp1 and Sp3 binding sites. J. Virol. 75:5240-5251.
58. Ragoczy, T., and G. Miller. 1999. Role of the Epstein-Barr virus RTA protein in activation of distinct classes of viral lytic cycle genes. J. Virol. 73:9858-9866.
59. Reeves, J. D., and A. J. Piefer. 2005. Emerging drug targets for antiretroviral therapy. Drugs 65:1747-1766.
60. Reischl, U., C. Gerdes, M. Motz, and H. Wolf. 1996. Expression and purification of an Epstein-Barr virus encoded 23-kDa protein and characterization of its immunological properties. J. Virol. Methods 57:71-85.
61. Serafini-Cessi, F., N. Malagolini, M. Nanni, F. Dall'Olio, G. Campadelli-Fiume, J. Tanner, and E. Kieff. 1989. Characterization of N- and O-linked oligosaccharides of glycoprotein 350 from Epstein-Barr virus. Virology 170:1-10.
62. Serio, T. R., J. L. Kolman, and G. Miller. 1997. Late gene expression from the Epstein-Barr virus BcLF1 and BFRF3 promoters does not require DNA replication in cis. J. Virol. 71:8726-8734.
63. Sinclair, A. J., M. Brimmell, F. Shanahan, and P. J. Farrell. 1991. Pathways of activation of the Epstein-Barr virus productive cycle. J. Virol. 65:2237-2244.
64. Sun, Z., J. Pan, W. X. Hope, S. N. Cohen, and S. P. Balk. 1999. Tumor susceptibility gene 101 protein represses androgen receptor transactivation and interacts with p300. Cancer 86:689-696.
65. Surjit, M., R. Oberoi, R. Kumar, and S. K. Lal. 2006. Enhanced alphal microglobulin secretion from Hepatitis E virus ORF3-expressing human hepatoma cells is mediated by the tumor susceptibility gene 101. J. Biol. Chem. 281:8135-8142.
66. Swenson, J. J., E. Holley-Guthrie, and S. C. Kenney. 2001. Epstein-Ban virus immediate-early protein BRLF1 interacts with CBP, promoting enhanced BRLF1 transactivation. J. Virol. 75:6228-6234.
67. Tsai, C. H., and R. Glaser. 1991. A comparison of Epstein-Barr virus specific proteins expressed by three Epstein-Barr virus isolates using specific monoclonal antibodies. Intervirology 32:376-382.
68. Tsai, C. H., M. T. Liu, M. R. Chen, J. Lu, H. L. Yang, J. Y. Chen, and C. S. Yang. 1997. Characterization of monoclonal antibodies to the Zta and DNase proteins of Epstein-Barr virus. J. Biomed. Sci. 4:69-77.
69. Urier, G., M. Buisson, P. Chambard, and A. Sergeant. 1989. The Epstein-Barr virus early protein EB1 activates transcription from different responsive elements including AP-1 binding sites. EMBO J. 8:1447-1453.
70. von Schwedler, U. K., M. Stuchell, B. Muller, D. M. Ward, H. Y. Chung, E. Morita, H. E. Wang, T. Davis, G. P. He, D. M. Cimbora, A. Scott, H. G. Krausslich, J. Kaplan, S. G. Morham, and W. I. Sundquist. 2003. The protein network of HIV budding. Cell 114:701-713.
71. Wagner, K. U., A. Krempler, Y. Qi, K. Park, M. D. Henry, A. A. Triplett, G. Riedlinger, I. E. Rucker, and L. Hennighausen. 2003. Tsg101 is essential for cell growth, proliferation, and cell survival of embryonic and adult tissues. Mol. Cell. Biol. 23:150-162.
72. Watanabe, M., Y. Yanagi, Y. Masuhiro, T. Yano, H. Yoshikawa, J. Yanagisawa, and S. Kato. 1998. A putative tumor suppressor, TSG101, acts as a transcriptional suppressor through its coiled-coil domain. Biochem. Biophys. Res. Commun. 245:900-905.
73. Yuan, J., E. Cahir-McFarland, B. Zhao, and E. Kieff. 2006. Virus and cell RNAs expressed during Epstein-Barr virus replication. J. Virol. 80:2548-2565.
74. Zhu, G., R. Gilchrist, N. Borley, H. W. Chng, M. Morgan, J. F. Marshall, R. S. Camplejohn, G. H. Muir, and I. R. Hart. 2004. Reduction of TSG101 protein has a negative impact on tumor cell growth. Int. J. Cancer 109:541-547.
75. zur Hausen, H., F. J. O'Neill, U. K. Freese, and E. Hecker. 1978. Persisting oncogenic herpesvirus induced by the tumour promotor TPA. Nature 272:373-375.